Full metadata record
DC FieldValueLanguage
dc.creatorMoreno, B. (Beatriz)-
dc.creatorLopez, I.P. (Iciar P.)-
dc.creatorFernandez-Diez, B. (B.)-
dc.creatorGottlieb, M. (Miroslav)-
dc.creatorMatute, C. (Carlos)-
dc.creatorSanchez-Gomez, M.V. (María Victoria)-
dc.creatorDomercq, M. (María)-
dc.creatorGiralt, A. (Albert)-
dc.creatorAlberch, J. (Jordi)-
dc.creatorCollon, K.W. (Kevin W.)-
dc.creatorZhang, H. (Helen)-
dc.creatorParent, J.M. (Jack M.)-
dc.creatorTeixido, M. (Meritxell)-
dc.creatorGiralt, E. (Ernest)-
dc.creatorCeña, V. (Valentín)-
dc.creatorPosadas, I. (Inmaculada)-
dc.creatorMartinez-Pinilla, E. (Eva)-
dc.creatorVilloslada, P. (Pablo)-
dc.creatorFranco, R. (Rafael)-
dc.identifier.citationMoreno B, Lopez I, Fernández-Díez B, Gottlieb M, Matute C, Sánchez-Gómez M.V, et al. Differential neuroprotective effects of 5'-Deoxy-5'-Methylthioadenosine. PLoS One. 2014 Mar;9(3):e90671.es_ES
dc.description.abstractBackground: 59-deoxy-59-methylthioadenosine (MTA) is an endogenous compound produced through the metabolism of polyamines. The therapeutic potential of MTA has been assayed mainly in liver diseases and, more recently, in animal models of multiple sclerosis. The aim of this study was to determine the neuroprotective effect of this molecule in vitro and to assess whether MTA can cross the blood brain barrier (BBB) in order to also analyze its potential neuroprotective efficacy in vivo. Methods: Neuroprotection was assessed in vitro using models of excitotoxicity in primary neurons, mixed astrocyte-neuron and primary oligodendrocyte cultures. The capacity of MTA to cross the BBB was measured in an artificial membrane assay and using an in vitro cell model. Finally, in vivo tests were performed in models of hypoxic brain damage, Parkinson’s disease and epilepsy. Results: MTA displays a wide array of neuroprotective activities against different insults in vitro. While the data from the two complementary approaches adopted indicate that MTA is likely to cross the BBB, the in vivo data showed that MTA may provide therapeutic benefits in specific circumstances. Whereas MTA reduced the neuronal cell death in pilocarpine-induced status epilepticus and the size of the lesion in global but not focal ischemic brain damage, it was ineffective in preserving dopaminergic neurons of the substantia nigra in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-mice model. However, in this model of Parkinson’s disease the combined administration of MTA and an A2A adenosine receptor antagonist did produce significant neuroprotection in this brain region. Conclusion: MTA may potentially offer therapeutic neuroprotection.es_ES
dc.publisherPublic Library of Sciencees_ES
dc.subjectIn vitroes_ES
dc.subjectIn vivoes_ES
dc.subjectFumaric acides_ES
dc.titleDifferential neuroprotective effects of 5'-Deoxy-5'-Methylthioadenosinees_ES

Files in This Item:
1.21 MB
Adobe PDF

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.